Publication: The blood stage antigen RBP2-P1 of plasmodium vivax binds reticulocytes and is a target of naturally acquired immunity
Issued Date
2020-03-01
Resource Type
ISSN
10985522
00199567
00199567
Other identifier(s)
2-s2.0-85082342164
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Infection and Immunity. Vol.88, No.4 (2020)
Suggested Citation
Anongruk Chim-Ong, Thitiporn Surit, Sittinont Chainarin, Wanlapa Roobsoong, Jetsumon Sattabongkot, Liwang Cui, Wang Nguitragool The blood stage antigen RBP2-P1 of plasmodium vivax binds reticulocytes and is a target of naturally acquired immunity. Infection and Immunity. Vol.88, No.4 (2020). doi:10.1128/IAI.00616-19 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/56208
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The blood stage antigen RBP2-P1 of plasmodium vivax binds reticulocytes and is a target of naturally acquired immunity
Other Contributor(s)
Abstract
Copyright © 2020 Chim-Ong et al. The interactions between Plasmodium parasites and human erythrocytes are prime targets of blood stage malaria vaccine development. The reticulocyte binding protein 2-P1 (RBP2-P1) of Plasmodium vivax, a member of the reticulocyte binding protein family, has recently been shown to be highly antigenic in several settings endemic for malaria. Yet, its functional characteristics and the relevance of its antibody response in human malaria have not been examined. In this study, the potential function of RBP2-P1 as an invasion ligand of P. vivax was evaluated. The protein was found to be expressed in schizonts, be localized at the apical end of the merozoite, and preferentially bind reticulocytes over normocytes. Human antibodies to this protein also exhibit erythrocyte binding inhibition at physiologically relevant concentrations. Furthermore, RBP2-P1 antibodies are associated with lower parasitemia and tend to be higher in asymptomatic carriers than in patients. This study provides evidence supporting a role of RBP2-P1 as an invasion ligand and its consideration as a vaccine target.